Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Cipla's US sales for the June quarter stood at $226 million, which was higher than the CNBC-TV18 poll estimate, that ranged ...

The Sensex fell 721 points and the Nifty 50 dropped 225 points amid foreign fund withdrawals. Analysts predict upcoming ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, ...

Total Income from operations rose to Rs 6,957 crore for the June quarter as compared with Rs 6,694 crore in the year-ago ...

The 100-day EMA zone of 24,600-24,550 will act as immediate support for the Nifty 50. Any sustainable move below the level of ...